Literature DB >> 33779841

Opsoclonus-myoclonus-ataxia syndrome in children.

Poonam Bhatia1,2, Jennifer Heim1, Patricia Cornejo2, Lauren Kane1,3, Jason Santiago1, Michael C Kruer4,5,6.   

Abstract

Opsoclonus-myoclonus-ataxia syndrome is a rare neuroimmunologic disorder typically presenting in previously healthy infants and toddlers. It is characterized by a clinical triad of (1) erratic saccadic intrusions; (2) myoclonus and/or ataxia; (3) behavioral features, typified by developmental plateauing, irritability and insomnia. About half of cases are associated with an underlying neuroblastoma and diagnostic imaging is essential once OMAS is suspected. A thorough workup, including serum, urine, and cerebrospinal fluid studies is critical to identify underlying biomarkers of OMAS itself or neuroblastoma. Historically, many children had relatively poor long-term outcomes, with residual neurologic and/or neuropsychiatry sequelae typical. More recent concepts have emphasized combined immunotherapy regimens that offer hope for better outcomes in children with this remarkable, challenging disease.
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Movement disorders; Neuroimmunology; Opsoclonus–myoclonus–ataxia; Pediatric

Mesh:

Year:  2021        PMID: 33779841     DOI: 10.1007/s00415-021-10536-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  2 in total

1.  IQ predictors in pediatric opsoclonus myoclonus syndrome: a large international cohort study.

Authors:  Andrew Sheridan; Kush Kapur; Ferne Pinard; Fabienne Dietrich Alber; Susana Camposano; Mike G Pike; Andrea Klein; Mark P Gorman
Journal:  Dev Med Child Neurol       Date:  2020-07-22       Impact factor: 5.449

2.  Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

Authors:  Pedro A de Alarcon; Katherine K Matthay; Wendy B London; Arlene Naranjo; Sheena C Tenney; Jessica A Panzer; Michael D Hogarty; Julie R Park; John M Maris; Susan L Cohn
Journal:  Lancet Child Adolesc Health       Date:  2017-11-03
  2 in total
  2 in total

1.  Opsoclonus myoclonus ataxia syndrome following COVID-19 infection.

Authors:  Ismail Ibrahim Ismail; Walaa A Kamel; Ayman Kilany
Journal:  Acta Neurol Belg       Date:  2022-07-14       Impact factor: 2.471

2.  Long-term neurological outcomes of children with neuroblastoma with opsoclonus-myoclonus syndrome.

Authors:  Qing Sun; Yinhao Wang; Yao Xie; Penghui Wu; Shuo Li; Weihong Zhao
Journal:  Transl Pediatr       Date:  2022-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.